Pamela Stephenson - Jul 22, 2022 Form 4/A - Amendment Insider Report for ALBIREO PHARMA, INC. (ALBO)

Role
Chief Commercial Officer
Signature
/s/ Jason Duncan, Attorney-in-fact
Stock symbol
ALBO
Transactions as of
Jul 22, 2022
Transactions value $
-$2,615
Form type
4/A - Amendment
Date filed
1/9/2023, 05:41 PM
Date Of Original Report
Jul 25, 2022
Previous filing
Jun 28, 2022
Next filing
Sep 27, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALBO Common Stock Sale -$2.62K -106 -0.23% $24.67 45.6K Jul 22, 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.67 to $24.7431, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 Represents 15,923 shares of common stock and 29,726 restricted stock units.

Remarks:

This amended Form 4 is being filed solely to correct the numbers of shares disclosed in column 5 of Table I and footnote 3, as the reporting person did not acquire 547 shares of common stock under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan on May 31, 2022.